Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00711828 · BASELINE

Baseline characteristics

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      21
    units
    Participants
groups
  1. description
    Rituximab 375 mg/m2 IV on day 1\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\> Dexamethasone 40 mg PO on days 1, 8, 15, 22
    id
    BG000
    title
    Treatment
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          51
          upper Limit
          80
          value
          69
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          8
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          13
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      21
    units
    Participants
groups
  1. description
    Rituximab 375 mg/m2 IV on day 1\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\> Dexamethasone 40 mg PO on days 1, 8, 15, 22
    id
    BG000
    title
    Treatment
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          51
          upper Limit
          80
          value
          69
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          8
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          13
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice